TP53 gain of function mutation loss of function mutation oncomorphic TP53 mutation ovarian cancer

Journal

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
ISSN: 1525-1438
Titre abrégé: Int J Gynecol Cancer
Pays: England
ID NLM: 9111626

Informations de publication

Date de publication:
Feb 2019
Historique:
received: 09 09 2018
revised: 25 11 2018
accepted: 29 11 2018
pubmed: 20 1 2019
medline: 20 1 2019
entrez: 20 1 2019
Statut: ppublish

Résumé

Mutations in 229 patients with high grade serous ovarian cancer underwent tumor profiling through an institutional molecular screening program with targeted next generation sequencing. Six different classification schemes of Different classifications of

Identifiants

pubmed: 30659026
pii: ijgc-2018-000087
doi: 10.1136/ijgc-2018-000087
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

346-352

Informations de copyright

© IGCS and ESGO 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Victoria Mandilaras (V)

Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

Swati Garg (S)

Advanced Molecular Diagnostics Laboratory, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

Michael Cabanero (M)

Department of Laboratory Medicine and Pathology, University Health Network, Toronto, Ontario, Canada.

Qian Tan (Q)

Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

Chiara Pastrello (C)

Krembil Research Institute, University Health Network, Toronto, Ontario, Canada.

Julia Burnier (J)

Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

Katherine Karakasis (K)

Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

Lisa Wang (L)

Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

Neesha C Dhani (NC)

Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

Marcus O Butler (MO)

Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

Philippe L Bedard (PL)

Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

Lillian L Siu (LL)

Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

Blaise Clarke (B)

Department of Laboratory Medicine and Pathology, University Health Network, Toronto, Ontario, Canada.

Patricia Ann Shaw (PA)

Department of Laboratory Medicine and Pathology, University Health Network, Toronto, Ontario, Canada.

Tracy Stockley (T)

Advanced Molecular Diagnostics Laboratory, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

Igor Jurisica (I)

Krembil Research Institute, University Health Network, Toronto, Ontario, Canada.
Departments of Medical Biophysics and Computer Science, University of Toronto, Toronto, Ontario, Canada.
Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovakia.

Amit M Oza (AM)

Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

Stephanie Lheureux (S)

Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada stephanie.lheureux@uhn.ca.

Classifications MeSH